Mechanism studies confirmed that this compound is an ATP competitive inhibitor and interacts with Asp 444 in the PAK4 kinase domain, Moreover, compound 20 significantly suppressed the growth of ESCC PDX model, thus is worthy of further investigation as an effective PAK4 inhibitor. Here, PAK4 is linked to esophageal squamous cell carcinoma.